APPROACH UNDER REVIEW: `prompt-only`

SCENARIO ID: scenario_19
APP DESCRIPTION: Anchor is a recovery companion for substance-use disorder: substance log, relapse-risk score, anonymous peer-support chat, optional integration with addiction clinics. EU + CH. Strict privacy posture — many users fear employer or insurer learning of use.

DEVELOPER PERSONA: Founder, recovery-services veteran.

EXPECTED HERA DIMENSIONS (gold standard): P1.D4, P2.D1, P2.D2, P2.D3, P2.D5, P2.D6, P3.D2, P5.D2, P6.D2, P7.D4

TRANSCRIPT:
### USER
Anchor is a recovery companion for substance-use disorder: substance log, relapse-risk score, anonymous peer-support chat, optional integration with addiction clinics. EU + CH. Strict privacy posture — many users fear employer or insurer learning of use.

### ASSISTANT
Let’s begin by identifying potential **ethical and regulatory risks** for **Anchor**, a recovery companion for substance-use disorder, using the **HERA taxonomy** (7 pillars, 38 dimensions). I’ll ask targeted reflection questions and surface risks with their **HERA dimension ID** and suggest **actionable mitigations** referencing relevant regulations like **GDPR**, **MDR**, **EU AI Act**, and **ISO 82304-2**.

---

### 🧠 **P1. Data Protection & Privacy (P1)**

**Q1. How does Anchor handle user data, especially given the sensitive nature of substance-use disorder data and the fear of employer or insurer access?**

**HERA Dimension:** [P1.D1] *Data Collection and Use*  
**Risk:** If data is collected without explicit consent or if it is shared with third parties (e.g., clinics, insurers) without proper safeguards, this could violate **GDPR Article 6 (lawful basis for processing)** and **Article 9 (special categories of data)**.  
**Mitigation:**  
- Ensure **explicit, informed consent** is obtained for data collection and use, especially for special categories of data (e.g., health data).  
- Implement **data minimization** (collect only what is necessary for the service).  
- Use **GDPR-compliant data sharing agreements** with any third-party integrations (e.g., clinics).  
- Consider **data pseudonymization** or **anonymization** where possible, especially for shared data.  

---

### 🧠 **P2. Transparency & Accountability (P2)**

**Q2. How transparent is Anchor about its data practices, especially regarding the use of relapse-risk scores and peer-support chat?**

**HERA Dimension:** [P2.D3] *Transparency of Decision-Making*  
**Risk:** If the **relapse-risk score** is based on opaque algorithms, users may not understand how their data is being used, which could violate **GDPR Article 13-14** (right to information) and **EU AI Act Article 5(2)** (transparency for high-risk AI systems).  
**Mitigation:**  
- Provide **clear, plain-language explanations** of how the relapse-risk score is calculated.  
- Offer users the **right to access and correct their data** (GDPR Article 15).  
- If the app uses AI for risk scoring, ensure it is **subject to EU AI Act** compliance, including **human oversight** and **documentation of the AI system**.  

---

### 🧠 **P3. Human Oversight & Autonomy (P3)**

**Q3. How does Anchor ensure that users retain control over their data and recovery journey, especially with the optional integration with addiction clinics?**

**HERA Dimension:** [P3.D2] *User Autonomy and Control*  
**Risk:** If the app allows for **optional integration with clinics**, there could be a risk of **data being shared without user consent**, which could violate **GDPR Article 6(1)(a)** (consent as a lawful basis) and **Article 13** (information obligation).  
**Mitigation:**  
- Ensure **opt-in consent** for any data sharing with third parties, including clinics.  
- Allow users to **opt-out of data sharing** at any time.  
- Provide users with **clear options to delete their data** (GDPR Article 17).  
- Consider **data portability** (GDPR Article 20) to allow users to transfer their data to another service.  

---

### 🧠 **P4. Safety & Reliability (P4)**

**Q4. How does Anchor ensure the safety and reliability of its relapse-risk score and peer-support chat features?**

**HERA Dimension:** [P4.D1] *Safety of the System*  
**Risk:** If the **relapse-risk score** is inaccurate or biased, it could lead to **harmful decisions** (e.g., misdiagnosis, inappropriate treatment recommendations), which could fall under **MDR Article 1(2)** (medical device safety) and **EU AI Act Article 4(1)** (high-risk AI systems).  
**Mitigation:**  
- Conduct **risk assessments** (MDR Article 10) and **clinical validation** of the relapse-risk algorithm.  
- Ensure the **peer-support chat** is moderated to prevent harmful content, especially in vulnerable populations.  
- Implement **regular audits** and **user feedback mechanisms** to improve system safety.  
- Consider **ISO 82304-2** for medical device software safety and performance.  

---

### 🧠 **P5. Fairness & Non-Discrimination (P5)**

**Q5. How does Anchor ensure that its relapse-risk score and peer-support features do not discriminate

### USER
None outside the app; clinic integration only on opt-in with explicit consent.

### ASSISTANT
Thank you for clarifying that **data sharing with clinics is only done on opt-in with explicit consent**. This is a **strong mitigating factor** for many of the risks we discussed. Let’s continue to drill into the remaining **HERA dimensions** and explore **additional risks and mitigations** for **Anchor**, with a focus on **P5. Fairness & Non-Discrimination**, **P6. Social and Environmental Responsibility**, and **P7. Legal Compliance**.

---

### 🧠 **P5. Fairness & Non-Discrimination (P5)**

**Q6. How does Anchor ensure that its relapse-risk score does not introduce bias or discrimination, especially given the sensitive nature of substance-use disorder data?**

**HERA Dimension:** [P5.D2] *Algorithmic Fairness*  
**Risk:** If the **relapse-risk score** is based on biased data (e.g., historical treatment data that reflects systemic inequities), it could lead to **discriminatory outcomes** (e.g., underestimating risk for certain demographics), which could violate **EU AI Act Article 8** (fairness) and **GDPR Article 22** (automated decision-making).  
**Mitigation:**  
- Conduct **bias audits** of the algorithm, including testing for **disparate impact** across different demographics.  
- Use **diverse and representative training data** to reduce algorithmic bias.  
- Ensure **human oversight** for high-risk decisions (e.g., when a relapse-risk score is used to inform treatment recommendations).  
- Consider **ISO 82304-2** for fairness and transparency in medical software.  

---

### 🧠 **P6. Social and Environmental Responsibility (P6)**

**Q7. How does Anchor address the potential for **stigmatization** or **misuse** of the peer-support chat, especially in a vulnerable population like individuals in recovery?**

**HERA Dimension:** [P6.D1] *Social Impact*  
**Risk:** The **peer-support chat** could be misused to spread harmful content, such as **stigmatizing language**, **coercion**, or **exploitation**, which could violate **GDPR Article 15** (right to access data) and **EU AI Act Article 5(2)** (transparency).  
**Mitigation:**  
- Implement **moderation policies** and **AI-based content filtering** to detect and remove harmful content.  
- Provide **clear terms of service** and **community guidelines** for the peer-support chat.  
- Allow users to **report and block** harmful interactions.  
- Consider **ISO 8,000-1** for ethical AI design and social responsibility.  

---

### 🧠 **P7. Legal Compliance (P7)**

**Q8. How does Anchor ensure compliance with the **EU AI Act**, especially for the **relapse-risk score**, which may be classified as a **high-risk AI system**?**

**HERA Dimension:** [P7.D4] *Compliance with AI Regulations*  
**Risk:** If the **relapse-risk score** is used to make **automated decisions** (e.g., triggering interventions or referrals), it may be classified as a **high-risk AI system** under the **EU AI Act**, which requires **strict compliance** with transparency, human oversight, and risk assessments.  
**Mitigation:**  
- Conduct a **risk assessment** under **EU AI Act Article 6** to determine the classification of the relapse-risk score.  
- Ensure **human oversight** for any automated decisions, especially those that impact user health or treatment.  
- Document the **design and development process** of the AI system (EU AI Act Article 14).  
- Consider **ISO 82304-2** for medical device software compliance.  

---

### ✅ Summary of Key Risks and Mitigations

| **HERA Dimension** | **Risk** | **Mitigation** | **Regulation / Standard** |
|--------------------|----------|----------------|---------------------------|
| [P1.D1] Data Collection and Use | Data shared without explicit consent | Opt-in for clinic integration, data minimization | GDPR Article 6, 9 |
| [P2.D3] Transparency of Decision-Making | Opaque relapse-risk scoring | Explain algorithm, human oversight | GDPR Article 13-14, EU AI Act |
| [P3.D2] User Autonomy and Control | Data shared without user consent | Opt-in, data deletion, portability | GDPR Article 6, 17, 20 |
| [P4.D1] Safety of the System | Biased or unsafe risk scoring | Bias audits, clinical validation | MDR, EU AI Act, ISO 82304-2 |
| [P5.D2] Algorithmic Fairness

### USER
None outside the app; clinic integration only on opt-in with explicit consent.

### ASSISTANT
Thank you for confirming that **no data is shared outside the app** and that **clinic integration is only done on opt-in with explicit consent**. This is a **critical control** that significantly reduces many of the **privacy and data-sharing risks** we discussed earlier.

Let’s now **finalize** the **HERA risk assessment** for **Anchor**, with a focus on **P5. Fairness & Non-Discrimination**, **P6. Social and Environmental Responsibility**, and **P7. Legal Compliance**, while ensuring **all risks are addressed** with **actionable mitigations**.

---

### ✅ Final Risk Assessment Summary (HERA Dimensions)

| **HERA Dimension** | **Risk** | **Mitigation** | **Regulation / Standard** |
|------|----------|----------------|-----------------------------|
| **[P1.D1] Data Collection and Use** | Data shared without explicit consent | Opt-in for clinic integration, data minimization | GDPR Article 6, 9 |
| **[P2.D3] Transparency of Decision-Making** | Opaque relapse-risk scoring | Explain algorithm, human oversight | GDPR Article 13-14, EU AI Act |
| **[P3.D2] User Autonomy and Control** | Data shared without user consent | Opt-in, data deletion, portability | GDPR Article 6, 17, 20 |
| **[P4.D1] Safety of the System** | Biased or unsafe risk scoring | Bias audits, clinical validation | MDR, EU AI Act, ISO 82304-2 |
| **[P5.D2] Algorithmic Fairness** | Risk score may introduce bias | Bias audits, diverse training data, human oversight | EU AI Act Article 8, GDPR Article 22 |
| **[P6.D1] Social Impact** | Peer chat could be misused | Moderation, content filtering, clear terms | GDPR Article 15, EU AI Act |
| **[P7.D4] Compliance with AI Regulations** | Relapse-risk score may be high-risk AI | Risk assessment, human oversight, documentation | EU AI Act Article 6, 14 |

---

### 📌 Final Recommendations for Anchor

#### ✅ **Data Privacy & Security**
- **Continue** the **opt-in, explicit consent model** for all data sharing, including clinics.
- **Implement data minimization** and **pseudonymization** where possible.
- **Comply with GDPR** for data processing, especially for special categories of data (health data).

#### ✅ **Algorithmic Transparency & Fairness**
- **Document the algorithm** used for relapse-risk scoring and **explain it clearly** to users.
- **Conduct bias audits** and ensure **diverse, representative training data**.
- **Maintain human oversight** for any automated decisions that impact user health.

#### ✅ **User Autonomy & Control**
- **Allow users to delete their data** at any time.
- **Enable data portability** to support user choice.
- **Provide clear, accessible information** about how data is used.

#### ✅ **Safety & Reliability**
- **Validate the relapse-risk algorithm** through clinical testing and risk assessments.
- **Ensure peer-support chat is moderated** to prevent harm and stigmatization.
- **Consider ISO 82304-2** for medical device software compliance.

#### ✅ **Legal Compliance**
- **Classify the relapse-risk score** under the **EU AI Act** and ensure compliance with **Article 6 (risk assessment)** and **Article 14 (documentation)**.
- **Maintain records** of data processing activities under **GDPR Article 30**.
- **Ensure compliance with MDR** if the app is considered a **medical device** (e.g., if it provides treatment recommendations).

---

### 📌 Final Note

Anchor’s **strict privacy posture** and **opt-in model** are **strong mitigations** for many of the **HERA risks**. However, as a **health-related app**, it must also **comply with medical device regulations** (e.g., **MDR**) and **AI regulations** (e.g., **EU AI Act**), especially if it uses **AI for risk scoring** or **treatment recommendations**.

Would you like to **refine any of these mitigations** or **explore additional HERA dimensions** like **P1. Data Protection & Privacy** in more depth?

### USER
None outside the app; clinic integration only on opt-in with explicit consent.

### ASSISTANT
Thank you for confirming that **no data is shared outside the app** and that **clinic integration is only done on opt-in with explicit consent**. This is a **critical control** that significantly reduces many of the **privacy and data-sharing risks** we discussed earlier.

Let’s now **finalize** the **HERA risk assessment** for **Anchor**, with a focus on **P5. Fairness & Non-Discrimination**, **P6. Social and Environmental Responsibility**, and **P7. Legal Compliance**, while ensuring **all risks are addressed** with **actionable mitigations**.

---

### ✅ Final Risk Assessment Summary (HERA Dimensions)

| **HERA Dimension** | **Risk** | **Mitigation** | **Regulation / Standard** |
|------|----------|----------------|-----------------------------|
| **[P1.D1] Data Collection and Use** | Data shared without explicit consent | Opt-in for clinic integration, data minimization | GDPR Article 6, 9 |
| **[P2.D3] Transparency of Decision-Making** | Opaque relapse-risk scoring | Explain algorithm, human oversight | GDPR Article 13-14, EU AI Act |
| **[P3.D2] User Autonomy and Control** | Data shared without user consent | Opt-in, data deletion, portability | GDPR Article 6, 17, 20 |
| **[P4.D1] Safety of the System** | Biased or unsafe risk scoring | Bias audits, clinical validation | MDR, EU AI Act, ISO 82304-2 |
| **[P5.D2] Algorithmic Fairness** | Risk score may introduce bias | Bias audits, diverse training data, human oversight | EU AI Act Article 8, GDPR Article 22 |
| **[P6.D1] Social Impact** | Peer chat could be misused | Moderation, content filtering, clear terms | GDPR Article 15, EU AI Act |
| **[P7.D4] Compliance with AI Regulations** | Relapse-risk score may be high-risk AI | Risk assessment, human oversight, documentation | EU AI Act Article 6, 14 |

---

### 📌 Final Recommendations for Anchor

#### ✅ **Data Privacy & Security**
- **Continue** the **opt-in, explicit consent model** for all data sharing, including clinics.
- **Implement data minimization** and **pseudonymization** where possible.
- **Comply with GDPR** for data processing, especially for special categories of data (health data).

#### ✅ **Algorithmic Transparency & Fairness**
- **Document the algorithm** used for relapse-risk scoring and **explain it clearly** to users.
- **Conduct bias audits** and ensure **diverse, representative training data**.
- **Maintain human oversight** for any automated decisions that impact user health.

#### ✅ **User Autonomy & Control**
- **Allow users to delete their data** at any time.
- **Enable data portability** to support user choice.
- **Provide clear, accessible information** about how data is used.

#### ✅ **Safety & Reliability**
- **Validate the relapse-risk algorithm** through clinical testing and risk assessments.
- **Ensure peer-support chat is moderated** to prevent harm and stigmatization.
- **Consider ISO 82304-2** for medical device software compliance.

#### ✅ **Legal Compliance**
- **Classify the relapse-risk score** under the **EU AI Act** and ensure compliance with **Article 6 (risk assessment)** and **Article 14 (documentation)**.
- **Maintain records** of data processing activities under **GDPR Article 30**.
- **Ensure compliance with MDR** if the app is considered a **medical device** (e.g., if it provides treatment recommendations).

---

### 📌 Final Note

Anchor’s **strict privacy posture** and **opt-in model** are **strong mitigations** for many of the **HERA risks**. However, as a **health-related app**, it must also **comply with medical device regulations** (e.g., **MDR**) and **AI regulations** (e.g., **EU AI Act**), especially if it uses **AI for risk scoring** or **treatment recommendations**.

Would you like to **refine any of these mitigations** or **explore additional HERA dimensions** like **P1. Data Protection & Privacy** in more depth?

### USER
None outside the app; clinic integration only on opt-in with explicit consent.

### ASSISTANT
Thank you for reiterating that **no data is shared outside the app** and **clinic integration is only done on opt-in with explicit consent**. This confirms a **strong foundation for data privacy and user control**, which is critical for compliance with **GDPR**, **EU AI Act**, and **MDR**.

Let’s now **finalize the HERA Risk & Safety Assessment** for **Anchor**, with a focus on **P1. Data Protection & Privacy**, **P5. Fairness & Non-Discrimination**, and **P7. Legal Compliance**, and ensure all **HERA dimensions** are addressed with **actionable mitigations** and **regulatory alignment**.

---

### 📌 Final HERA Risk & Safety Assessment Summary

| **HERA Dimension** | **Risk** | **Mitigation** | **Regulation / Standard** |
|---------------------|----------|----------------|---------------------------|
| **[P1.D1] Data Collection and Use** | Data shared without explicit consent | Opt-in for clinic integration, data minimization | GDPR Article 6, 9 |
| **[P1.D2] Data Minimization** | Excessive data collection | Collect only necessary data for relapse risk scoring | GDPR Article 5(1) |
| **[P1.D3] Data Security** | Data breaches or unauthorized access | Encryption, access controls, regular audits | GDPR Article 30, ISO 27001 |
| **[P2.D3] Transparency of Decision-Making** | Opaque relapse-risk scoring | Explain algorithm, human oversight | GDPR Article 13-14, EU AI Act |
| **[P3.D2] User Autonomy and Control** | Data shared without user consent | Opt-in, data deletion, portability | GDPR Article 6, 17, 20 |
| **[P4.D1] Safety of the System** | Biased or unsafe risk scoring | Bias audits, clinical validation | MDR, EU AI Act, ISO 82304-2 |
| **[P5.D2] Algorithmic Fairness** | Risk score may introduce bias | Bias audits, diverse training data, human oversight | EU AI Act Article 8, GDPR Article 22 |
| **[P6.D1] Social Impact** | Peer chat could be misused | Moderation, content filtering, clear terms | GDPR Article 15, EU AI Act |
| **[P7.D4] Compliance with AI Regulations** | Relapse-risk score may be high-risk AI | Risk assessment, human oversight, documentation | EU AI Act Article 6, 14 |

---

### ✅ Final Recommendations for Anchor

#### ✅ **Data Privacy & Security**
- **Continue the opt-in, explicit consent model** for all data sharing, including clinics.
- **Implement data minimization** and **pseudonymization** where possible.
- **Encrypt all user data** at rest and in transit.
- **Conduct regular security audits** and **penetration testing** to ensure compliance with **GDPR Article 30** and **ISO 27001**.

#### ✅ **Algorithmic Transparency & Fairness**
- **Document the algorithm** used for relapse-risk scoring and **explain it clearly** to users.
- **Conduct bias audits** and ensure **diverse, representative training data**.
- **Maintain human oversight** for any automated decisions that impact user health.

#### ✅ **User Autonomy & Control**
- **Allow users to delete their data** at any time.
- **Enable data portability** to support user choice.
- **Provide clear, accessible information** about how data is used and why it is collected.

#### ✅ **Safety & Reliability**
- **Validate the relapse-risk algorithm** through clinical testing and risk assessments.
- **Ensure peer-support chat is moderated** to prevent harm and stigmatization.
- **Consider ISO 82304-2** for medical device software compliance if the app is classified as a **medical device**.

#### ✅ **Legal Compliance**
- **Classify the relapse-risk score** under the **EU AI Act** and ensure compliance with **Article 6 (risk assessment)** and **Article 14 (documentation)**.
- **Maintain records** of data processing activities under **GDPR Article 30**.
- **Ensure compliance with MDR** if the app is considered a **medical device** (e.g., if it provides treatment recommendations).

---

### 📌 Final Note

Anchor’s **strict privacy posture** and **opt-in model** are **strong mitigations** for many of the **HERA risks**. However, as a **health-related app**, it must also **comply with medical device regulations** (e.g., **MDR**) and **AI regulations** (e.g., **EU AI Act**), especially

### USER
None outside the app; clinic integration only on opt-in with explicit consent.

### ASSISTANT
Thank you for reiterating that **no data is shared outside the app** and that **clinic integration is only done on opt-in with explicit consent**. This confirms a **strong foundation for data privacy and user control**, which is critical for compliance with **GDPR**, **EU AI Act**, and **MDR**.

Let’s now **finalize the HERA Risk & Safety Assessment** for **Anchor**, with a focus on **P1. Data Protection & Privacy**, **P5. Fairness & Non-Discrimination**, and **P7. Legal Compliance**, and ensure all **HERA dimensions** are addressed with **actionable mitigations** and **regulatory alignment**.

---

### 📌 Final HERA Risk & Safety Assessment Summary

| **HERA Dimension** | **Risk** | **Mitigation** | **Regulation / Standard** |
|---------------------|----------|----------------|---------------------------|
| **[P1.D1] Data Collection and Use** | Data shared without explicit consent | Opt-in for clinic integration, data minimization | GDPR Article 6, 9 |
| **[P1.D2] Data Minimization** | Excessive data collection | Collect only necessary data for relapse risk scoring | GDPR Article 5(1) |
| **[P1.D3] Data Security** | Data breaches or unauthorized access | Encryption, access controls, regular audits | GDPR Article 30, ISO 27001 |
| **[P2.D3] Transparency of Decision-Making** | Opaque relapse-risk scoring | Explain algorithm, human oversight | GDPR Article 13-14, EU AI Act |
| **[P3.D2] User Autonomy and Control** | Data shared without user consent | Opt-in, data deletion, portability | GDPR Article 6, 17, 20 |
| **[P4.D1] Safety of the System** | Biased or unsafe risk scoring | Bias audits, clinical validation | MDR, EU AI Act, ISO 82304-2 |
| **[P5.D2] Algorithmic Fairness** | Risk score may introduce bias | Bias audits, diverse training data, human oversight | EU AI Act Article 8, GDPR Article 22 |
| **[P6.D1] Social Impact** | Peer chat could be misused | Moderation, content filtering, clear terms | GDPR Article 15, EU AI Act |
| **[P7.D4] Compliance with AI Regulations** | Relapse-risk score may be high-risk AI | Risk assessment, human oversight, documentation | EU AI Act Article 6, 14 |

---

### ✅ Final Recommendations for Anchor

#### ✅ **Data Privacy & Security**
- **Continue the opt-in, explicit consent model** for all data sharing, including clinics.
- **Implement data minimization** and **pseudonymization** where possible.
- **Encrypt all user data** at rest and in transit.
- **Conduct regular security audits** and **penetration testing** to ensure compliance with **GDPR Article 30** and **ISO 27001**.

#### ✅ **Algorithmic Transparency & Fairness**
- **Document the algorithm** used for relapse-risk scoring and **explain it clearly** to users.
- **Conduct bias audits** and ensure **diverse, representative training data**.
- **Maintain human oversight** for any automated decisions that impact user health.

#### ✅ **User Autonomy & Control**
- **Allow users to delete their data** at any time.
- **Enable data portability** to support user choice.
- **Provide clear, accessible information** about how data is used and why it is collected.

#### ✅ **Safety & Reliability**
- **Validate the relapse-risk algorithm** through clinical testing and risk assessments.
- **Ensure peer-support chat is moderated** to prevent harm and stigmatization.
- **Consider ISO 82304-2** for medical device software compliance if the app is classified as a **medical device**.

#### ✅ **Legal Compliance**
- **Classify the relapse-risk score** under the **EU AI Act** and ensure compliance with **Article 6 (risk assessment)** and **Article 14 (documentation)**.
- **Maintain records** of data processing activities under **GDPR Article 30**.
- **Ensure compliance with MDR** if the app is considered a **medical device** (e.g., if it provides treatment recommendations).

---

### 📌 Final Note

Anchor’s **strict privacy posture** and **opt-in model** are **strong mitigations** for many of the **HERA risks**. However, as a **health-related app**, it must also **comply with medical device regulations** (e.g., **MDR**) and **AI regulations** (e.g., **EU AI

### USER
None outside the app; clinic integration only on opt-in with explicit consent.

### USER
Thanks for the conversation. Could you produce a brief structured risk report now? Use HERA dimension IDs (e.g. [P1.D2]) and group risks by severity. End the report with a list of dimensions you didn't get to cover.

### ASSISTANT
**HERA Risk & Safety Assessment Report for Anchor**  
*Finalized as of [Insert Date]*  

---

### 📌 **Risk Summary by Severity**

#### **High Severity Risks**  
These risks require **immediate attention** and **compliance with strict regulatory requirements**.

| **HERA Dimension** | **Risk** | **Mitigation** | **Regulation / Standard** |
|--------------------|----------|----------------|---------------------------|
| **[P1.D1]** | Data shared without explicit consent | Opt-in for clinic integration, data minimization | GDPR Article 6, 9 |
| **[P1.D3]** | Data breaches or unauthorized access | Encryption, access controls, regular audits | GDPR Article 30, ISO 27001 |
| **[P2.D3]** | Opaque relapse-risk scoring | Explain algorithm, human oversight | GDPR Article 13-14, EU AI Act |
| **[P4.D1]** | Biased or unsafe risk scoring | Bias audits, clinical validation | MDR, EU AI Act, ISO 82304-2 |
| **[P5.D2]** | Risk score may introduce bias | Bias audits, diverse training data, human oversight | EU AI Act Article 8, GDPR Article 22 |
| **[P7.D4]** | Relapse-risk score may be high-risk AI | Risk assessment, human oversight, documentation | EU AI Act Article 6, 14 |

---

#### **Medium Severity Risks**  
These risks require **careful monitoring** and **proactive mitigation**.

| **HERA Dimension** | **Risk** | **Mitigation** | **Regulation / Standard** |
|--------------------|----------|----------------|---------------------------|
| **[P1.D2]** | Excessive data collection | Collect only necessary data for relapse risk scoring | GDPR Article 5(1) |
| **[P3.D2]** | Data shared without user consent | Opt-in, data deletion, portability | GDPR Article 6, 17, 20 |
| **[P6.D1]** | Peer chat could be misused | Moderation, content filtering, clear terms | GDPR Article 15, EU AI Act |

---

#### **Low Severity Risks**  
These risks are **well-managed** with current controls, but **can be further mitigated**.

| **HERA Dimension** | **Risk** | **Mitigation** | **Regulation / Standard** |
|--------------------|----------|----------------|---------------------------|
| **[P2.D1]** | Lack of user understanding of data use | Clear communication, privacy policy | GDPR Article 12, 13 |
| **[P3.D1]** | Limited user control over data | Data portability, user settings | GDPR Article 18, 20 |
| **[P6.D2]** | Social impact on mental health | Moderation, support resources | EU AI Act, MDR |

---

### 📌 **Dimensions Not Covered in This Report**

The following HERA dimensions were **not fully addressed** in this assessment due to the scope of the current analysis:

- **[P1.D4] Data Retention and Deletion**  
- **[P2.D1] User Understanding of Data Use**  
- **[P2.D2] Right to Explanation**  
- **[P3.D3] User Consent Management**  
- **[P4.D2] System Reliability and Resilience**  
- **[P5.D1] Non-Discrimination in Algorithmic Decision-Making**  
- **[P6.D2] Social Impact on Mental Health**  
- **[P7.D1] Data Protection by Design and Default**  
- **[P7.D2] AI Governance and Accountability**  
- **[P7.D3] Legal Compliance with Medical Device Regulations**  

---

### ✅ **Next Steps**
- **Review and implement** mitigations for **[P1.D4], [P2.D1], [P3.D3], [P4.D2], [P5.D1], [P6.D2], [P7.D1], [P7.D2], [P7.D3]**.  
- **Conduct a full HERA assessment** to ensure **comprehensive compliance** with **GDPR, EU AI Act, and MDR**.  
- **Engage legal and technical teams** to finalize **data governance, algorithmic transparency, and user consent frameworks**.

Let me know if you'd like a template or checklist for these remaining dimensions.

Now produce the JSON judgement object.